ESTABLISHMENT AND MEMBERSHIP. 1. To assist the Department in the administration of this Agreement, an Advisory board, to be known as the California Leafy Green Advisory Board, is hereby established. The Board shall consist of no less than seven (7) and no more than thirteen (13) Signatory Handler members, with the exact number of members to be determined by the Board. However, the initial board shall consist of 13 members comprised of members as described in sub-paragraph a through c, below:
ESTABLISHMENT AND MEMBERSHIP. 1. The Contracting Parties shall establish a Fund for ASEAN (hereinafter called “the Fund”).
ESTABLISHMENT AND MEMBERSHIP. The Contracting Parties shall establish an ASEAN CULTURAL FUND (hereinafter referred to as the Cultural Fund). Members of ASEAN shall be members of the Cultural Fund.
ESTABLISHMENT AND MEMBERSHIP. Within thirty (30) days of the Effective Date, the Parties shall establish a joint steering committee (the “JSC”) to coordinate and oversee the Development and Commercialization of the Licensed Products as contemplated by this Agreement.
ESTABLISHMENT AND MEMBERSHIP. 1.1. The board shall be called the Partnership Board, the Partnership Board or the Board
ESTABLISHMENT AND MEMBERSHIP. 1. The Contracting Parties shall establish an ASEAN+3 Finance Cooperation Fund (hereinafter referred to as “the Fund”) to provide financial support for the ASEAN+3 finance meetings.
ESTABLISHMENT AND MEMBERSHIP. 1. To assist the department in the administration of this Agreement, an advisory board, to be known as the California Pistachio Board, is hereby established. The board shall consist of one
ESTABLISHMENT AND MEMBERSHIP. As of the Effective Date, Company and Teva will appoint a Joint Research Committee to monitor and coordinate all aspects of the R&D Program (the “Joint Research Committee” or “JRC”). Each Party will designate two (2) representatives with appropriate expertise to serve as members of the JRC. Each Party may replace its representatives on the JRC at any time upon written notice to the other Party. Each Party shall alternate in designating one of their representatives to the JRC to serve as its chairman for a one-year term. Teva will select from its representatives the initial chairperson for the JRC. From time to time during the term of any chairperson, either Party may change the representative nominated by such Party who will serve as chairperson on written notice to the other Party. The initial members of the JRC are set forth in Annex 2. [*] Designates portions of this document that have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.
ESTABLISHMENT AND MEMBERSHIP. As of the Effective Date, the Company and PH will appoint a Joint Collaboration Committee to monitor and coordinate all aspects of the relationship between the Parties (the “Joint Collaboration Committee” or “JCC”). Each Party will designate two (2) representatives with appropriate expertise to serve as members of the JCC. Each Party may replace its representatives on the JCC at any time upon written notice to the other Party. Each Party shall alternate in designating one of their representatives to the JCC to serve as its chairperson for a one-year term. PH will select from its representatives the initial chairperson for the JCC. From time to time during the term of any chairperson, either Party may change the representative nominated by such Party who will serve as chairperson on written notice to the other Party.
ESTABLISHMENT AND MEMBERSHIP. As soon as practicable following the Exercise of the License Option by Teva with respect to a Target, Company and Teva will appoint a Joint Development Committee to share information regarding the development and commercialization of a Licensed Product and each subsequent Licensed Product with respect to such Target (the “Joint Development Committee” or “JDC”). Each Party will designate two (2) representatives with appropriate expertise to serve as members of the JDC. Each Party may replace its representatives on the JDC at any time upon written notice to the other Party. Teva will select from its representatives the chairperson for the JDC. From time to time during the term of any chairperson, Teva may change the representative who will serve as chairperson on written notice to Company. The initial members of the JDC will be designated by the Parties upon the first Exercise of a License Option.
